Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 27 | 2024 | 144 | 5.720 |
Why?
|
| Breast Neoplasms | 21 | 2024 | 1502 | 4.810 |
Why?
|
| Patient Readmission | 6 | 2023 | 73 | 4.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 182 | 3.230 |
Why?
|
| Decision Making | 9 | 2021 | 203 | 2.680 |
Why?
|
| Receptor, erbB-2 | 10 | 2020 | 133 | 2.240 |
Why?
|
| Models, Economic | 8 | 2024 | 20 | 1.820 |
Why?
|
| Decision Support Techniques | 7 | 2020 | 47 | 1.780 |
Why?
|
| Delivery of Health Care | 8 | 2024 | 276 | 1.720 |
Why?
|
| Technology Assessment, Biomedical | 3 | 2024 | 7 | 1.640 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 75 | 1.570 |
Why?
|
| Retrospective Studies | 17 | 2024 | 2026 | 1.460 |
Why?
|
| Humans | 62 | 2024 | 37093 | 1.430 |
Why?
|
| Drug Costs | 5 | 2020 | 28 | 1.420 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 113 | 1.340 |
Why?
|
| Hospital Mortality | 2 | 2020 | 187 | 1.320 |
Why?
|
| United States | 24 | 2024 | 4223 | 1.230 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 803 | 1.150 |
Why?
|
| Hospitalization | 5 | 2024 | 388 | 1.130 |
Why?
|
| Female | 33 | 2024 | 20969 | 1.110 |
Why?
|
| Opioid-Related Disorders | 3 | 2024 | 125 | 1.010 |
Why?
|
| Mastectomy, Segmental | 3 | 2022 | 17 | 0.950 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 33 | 0.920 |
Why?
|
| Quality-Adjusted Life Years | 11 | 2022 | 44 | 0.920 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 142 | 0.830 |
Why?
|
| Critical Illness | 1 | 2022 | 38 | 0.820 |
Why?
|
| Aged | 17 | 2024 | 6741 | 0.820 |
Why?
|
| Hepatic Encephalopathy | 1 | 2021 | 11 | 0.790 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 16 | 0.770 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 62 | 0.770 |
Why?
|
| Risk Factors | 8 | 2024 | 3562 | 0.770 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 39 | 0.770 |
Why?
|
| Azithromycin | 1 | 2020 | 6 | 0.760 |
Why?
|
| Logistic Models | 4 | 2023 | 923 | 0.750 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 36 | 0.740 |
Why?
|
| Frail Elderly | 1 | 2020 | 14 | 0.740 |
Why?
|
| Attitude to Death | 1 | 2020 | 21 | 0.730 |
Why?
|
| Antimalarials | 1 | 2020 | 55 | 0.730 |
Why?
|
| Length of Stay | 4 | 2023 | 185 | 0.720 |
Why?
|
| Life Expectancy | 1 | 2020 | 42 | 0.720 |
Why?
|
| Databases, Factual | 4 | 2023 | 291 | 0.720 |
Why?
|
| Markov Chains | 6 | 2020 | 35 | 0.720 |
Why?
|
| Immunotherapy | 1 | 2021 | 95 | 0.720 |
Why?
|
| Stroke | 2 | 2020 | 286 | 0.700 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 151 | 0.700 |
Why?
|
| Sirolimus | 3 | 2014 | 60 | 0.700 |
Why?
|
| Pyridines | 1 | 2020 | 116 | 0.690 |
Why?
|
| Piperazines | 1 | 2020 | 111 | 0.690 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 94 | 0.680 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 160 | 0.670 |
Why?
|
| Quality of Life | 3 | 2019 | 481 | 0.650 |
Why?
|
| Treatment Outcome | 7 | 2020 | 1369 | 0.650 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 352 | 0.640 |
Why?
|
| Longevity | 1 | 2020 | 147 | 0.640 |
Why?
|
| Incretins | 1 | 2018 | 1 | 0.630 |
Why?
|
| Brain Ischemia | 1 | 2020 | 184 | 0.630 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 9 | 0.630 |
Why?
|
| Androstadienes | 2 | 2014 | 18 | 0.610 |
Why?
|
| Health Care Costs | 4 | 2024 | 77 | 0.610 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 336 | 0.610 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 24 | 0.600 |
Why?
|
| Genetic Testing | 1 | 2018 | 75 | 0.600 |
Why?
|
| Attitude to Health | 1 | 2020 | 325 | 0.590 |
Why?
|
| Adult | 14 | 2023 | 11712 | 0.590 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 219 | 0.570 |
Why?
|
| Medicare | 9 | 2024 | 195 | 0.550 |
Why?
|
| Time Factors | 5 | 2021 | 1742 | 0.550 |
Why?
|
| Blood Glucose | 1 | 2018 | 353 | 0.530 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 905 | 0.530 |
Why?
|
| Hormones | 1 | 2015 | 55 | 0.510 |
Why?
|
| Peptides | 1 | 2018 | 320 | 0.500 |
Why?
|
| Thiocarbamates | 1 | 2014 | 4 | 0.490 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2011 | 18 | 0.480 |
Why?
|
| Budgets | 1 | 2014 | 9 | 0.480 |
Why?
|
| Child | 5 | 2022 | 3131 | 0.480 |
Why?
|
| Reimbursement Mechanisms | 1 | 2013 | 10 | 0.470 |
Why?
|
| Economics, Medical | 1 | 2013 | 3 | 0.470 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 15 | 0.460 |
Why?
|
| Middle Aged | 10 | 2022 | 10129 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 643 | 0.440 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 275 | 0.420 |
Why?
|
| Formularies as Topic | 1 | 2011 | 3 | 0.410 |
Why?
|
| Hepatitis C, Chronic | 2 | 2022 | 39 | 0.400 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 2721 | 0.400 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 37 | 0.400 |
Why?
|
| Developing Countries | 1 | 2011 | 99 | 0.390 |
Why?
|
| Cote d'Ivoire | 3 | 2020 | 6 | 0.390 |
Why?
|
| Decision Trees | 3 | 2020 | 19 | 0.380 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 2379 | 0.380 |
Why?
|
| Prescription Drugs | 1 | 2011 | 30 | 0.380 |
Why?
|
| Child, Preschool | 4 | 2024 | 1418 | 0.360 |
Why?
|
| Melanoma | 2 | 2021 | 96 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 268 | 0.340 |
Why?
|
| Young Adult | 6 | 2021 | 4268 | 0.340 |
Why?
|
| Male | 11 | 2024 | 20025 | 0.330 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 198 | 0.330 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 227 | 0.330 |
Why?
|
| Physicians | 1 | 2011 | 163 | 0.330 |
Why?
|
| Choice Behavior | 2 | 2021 | 79 | 0.320 |
Why?
|
| Norpregnenes | 1 | 2007 | 2 | 0.310 |
Why?
|
| Hot Flashes | 1 | 2007 | 7 | 0.310 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 19 | 0.310 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 44 | 0.300 |
Why?
|
| Risk Assessment | 2 | 2020 | 753 | 0.300 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 404 | 0.290 |
Why?
|
| Adolescent | 4 | 2021 | 5363 | 0.280 |
Why?
|
| Taxoids | 2 | 2017 | 37 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 128 | 0.270 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 33 | 0.270 |
Why?
|
| Health Resources | 2 | 2016 | 32 | 0.250 |
Why?
|
| Probability | 2 | 2016 | 78 | 0.250 |
Why?
|
| Disease Progression | 3 | 2020 | 601 | 0.250 |
Why?
|
| Hepacivirus | 2 | 2022 | 62 | 0.240 |
Why?
|
| Health Care Sector | 1 | 2024 | 7 | 0.240 |
Why?
|
| Medication Adherence | 2 | 2024 | 179 | 0.240 |
Why?
|
| Postmenopause | 2 | 2019 | 128 | 0.240 |
Why?
|
| Endrin | 1 | 2024 | 2 | 0.240 |
Why?
|
| Cost of Illness | 1 | 2024 | 76 | 0.240 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 730 | 0.230 |
Why?
|
| Aortic Aneurysm | 1 | 2023 | 4 | 0.230 |
Why?
|
| Canada | 3 | 2016 | 130 | 0.230 |
Why?
|
| Antiviral Agents | 2 | 2022 | 157 | 0.230 |
Why?
|
| Insurance, Health | 1 | 2024 | 126 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 664 | 0.220 |
Why?
|
| Drug Users | 1 | 2022 | 46 | 0.210 |
Why?
|
| Florida | 2 | 2021 | 410 | 0.200 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 103 | 0.200 |
Why?
|
| Propensity Score | 2 | 2023 | 38 | 0.200 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 61 | 0.200 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 121 | 0.200 |
Why?
|
| Hepatitis C | 1 | 2022 | 125 | 0.200 |
Why?
|
| Hospital Costs | 1 | 2021 | 24 | 0.190 |
Why?
|
| Patient Preference | 1 | 2021 | 44 | 0.190 |
Why?
|
| Refuse Disposal | 1 | 2021 | 18 | 0.190 |
Why?
|
| Torsades de Pointes | 1 | 2020 | 2 | 0.190 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 5 | 0.190 |
Why?
|
| Papillomaviridae | 1 | 2022 | 127 | 0.190 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 17 | 0.190 |
Why?
|
| Long QT Syndrome | 1 | 2020 | 13 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 22 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2022 | 1378 | 0.190 |
Why?
|
| Legislation, Drug | 1 | 2020 | 5 | 0.190 |
Why?
|
| Radiotherapy | 1 | 2020 | 18 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 400 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2020 | 51 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2023 | 1492 | 0.180 |
Why?
|
| Drugs, Generic | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 77 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 14 | 0.180 |
Why?
|
| Taiwan | 1 | 2019 | 14 | 0.180 |
Why?
|
| Vaccination | 1 | 2022 | 288 | 0.180 |
Why?
|
| Electrocardiography | 1 | 2020 | 156 | 0.180 |
Why?
|
| Survival Rate | 1 | 2020 | 311 | 0.180 |
Why?
|
| Quinolines | 1 | 2020 | 64 | 0.170 |
Why?
|
| Nitriles | 1 | 2019 | 69 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2021 | 134 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 111 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 88 | 0.170 |
Why?
|
| Computer Simulation | 2 | 2020 | 362 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2020 | 102 | 0.170 |
Why?
|
| Triazoles | 1 | 2019 | 86 | 0.170 |
Why?
|
| Monte Carlo Method | 2 | 2016 | 57 | 0.160 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 101 | 0.160 |
Why?
|
| Ticlopidine | 1 | 2018 | 15 | 0.160 |
Why?
|
| Maytansine | 1 | 2017 | 1 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 26 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2018 | 325 | 0.150 |
Why?
|
| Adenosine | 1 | 2018 | 59 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 16 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 12 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 41 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 485 | 0.140 |
Why?
|
| Hypoglycemia | 1 | 2016 | 17 | 0.140 |
Why?
|
| Mexico | 1 | 2017 | 240 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 148 | 0.140 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 458 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2018 | 339 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 358 | 0.140 |
Why?
|
| Prevalence | 1 | 2020 | 1455 | 0.130 |
Why?
|
| Vinblastine | 1 | 2015 | 9 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2015 | 17 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2015 | 26 | 0.130 |
Why?
|
| Accidental Falls | 1 | 2015 | 26 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 1033 | 0.120 |
Why?
|
| Decision Making, Organizational | 1 | 2014 | 6 | 0.120 |
Why?
|
| Incidence | 3 | 2024 | 922 | 0.120 |
Why?
|
| Health Records, Personal | 1 | 2014 | 5 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 63 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2014 | 30 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 610 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 81 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 156 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 204 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2013 | 217 | 0.100 |
Why?
|
| Health Priorities | 1 | 2011 | 19 | 0.100 |
Why?
|
| National Health Programs | 1 | 2011 | 17 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2011 | 208 | 0.090 |
Why?
|
| Algorithms | 1 | 2014 | 465 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2024 | 894 | 0.090 |
Why?
|
| Infant | 2 | 2024 | 1046 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2018 | 1908 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 560 | 0.080 |
Why?
|
| Social Class | 1 | 2011 | 247 | 0.080 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 11 | 0.080 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2007 | 11 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 143 | 0.070 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2024 | 8 | 0.060 |
Why?
|
| Prescriptions | 1 | 2024 | 18 | 0.060 |
Why?
|
| SEER Program | 1 | 2024 | 91 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2023 | 7 | 0.060 |
Why?
|
| Macrolides | 1 | 2023 | 11 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 50 | 0.050 |
Why?
|
| Survivors | 1 | 2024 | 136 | 0.050 |
Why?
|
| Uncertainty | 1 | 2022 | 26 | 0.050 |
Why?
|
| Glucosides | 1 | 2022 | 16 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 197 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 43 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 28 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2021 | 38 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2022 | 238 | 0.050 |
Why?
|
| Australia | 1 | 2020 | 76 | 0.050 |
Why?
|
| Palliative Care | 1 | 2020 | 49 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 3 | 0.050 |
Why?
|
| Aspirin | 1 | 2020 | 49 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 224 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 170 | 0.040 |
Why?
|
| Research Design | 1 | 2019 | 313 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 561 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 12 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 712 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 677 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 50 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 65 | 0.030 |
Why?
|
| Bibliometrics | 1 | 2014 | 17 | 0.030 |
Why?
|
| Insulin | 1 | 2016 | 236 | 0.030 |
Why?
|